Literature DB >> 21299192

In vivo formation of a glutathione conjugate derived from thalidomide in humanized uPA-NOG mice.

Hiroshi Yamazaki1, Hiroshi Suemizu, Sho Igaya, Makiko Shimizu, Norio Shibata, Masato Nakamura, Goutam Chowdhury, F Peter Guengerich.   

Abstract

Metabolism of the teratogen thalidomide is proposed to be relevant to its toxicological action. We demonstrated the formation of the glutathione (GSH) conjugate of (R)-5-hydroxythalidomide in vivo in chimeric NOD-scid IL2Rg(null) mice with humanized livers (uPA-NOG mice). After an oral administration of racemic thalidomide (270 mg/kg), plasma concentrations of 5-hydroxythalidomide were significantly higher in humanized mice than in control mice. The GSH conjugate of 5-hydroxythalidomide was detected in the plasma. These results indicate that livers of humanized mice mediate thalidomide 5-hydroxylation and further oxidation leading to the GSH conjugate in vivo as well as in vitro and suggest that thalidomide activation occurs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21299192      PMCID: PMC3838788          DOI: 10.1021/tx200005g

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  21 in total

1.  Human liver microsomal cytochrome P450 3A enzymes involved in thalidomide 5-hydroxylation and formation of a glutathione conjugate.

Authors:  Goutam Chowdhury; Norie Murayama; Yusuke Okada; Yasuhiro Uno; Makiko Shimizu; Norio Shibata; F Peter Guengerich; Hiroshi Yamazaki
Journal:  Chem Res Toxicol       Date:  2010-06-21       Impact factor: 3.739

Review 2.  A short history of thalidomide embryopathy.

Authors:  W Lenz
Journal:  Teratology       Date:  1988-09

3.  Thalidomide revisited: pharmacology and clinical applications.

Authors:  L Calabrese; K Resztak
Journal:  Expert Opin Investig Drugs       Date:  1998-12       Impact factor: 6.206

4.  The metabolism of thalidomide: the fate of thalidomide and some of its hydrolysis products in various species.

Authors:  H Schumacher; R L Smith; R T Williams
Journal:  Br J Pharmacol Chemother       Date:  1965-10

5.  Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients.

Authors:  S K Teo; P J Sabourin; K O'Brien; K A Kook; S D Thomas
Journal:  J Biochem Mol Toxicol       Date:  2000       Impact factor: 3.642

6.  Identification of a primary target of thalidomide teratogenicity.

Authors:  Takumi Ito; Hideki Ando; Takayuki Suzuki; Toshihiko Ogura; Kentaro Hotta; Yoshimasa Imamura; Yuki Yamaguchi; Hiroshi Handa
Journal:  Science       Date:  2010-03-12       Impact factor: 47.728

7.  Establishment of a humanized model of liver using NOD/Shi-scid IL2Rgnull mice.

Authors:  Hiroshi Suemizu; Masami Hasegawa; Kenji Kawai; Kenji Taniguchi; Makoto Monnai; Masatoshi Wakui; Makoto Suematsu; Mamoru Ito; Gary Peltz; Masato Nakamura
Journal:  Biochem Biophys Res Commun       Date:  2008-10-07       Impact factor: 3.575

8.  A new method for determination of both thalidomide enantiomers using HPLC systems.

Authors:  Kaname Sembongi; Masanori Tanaka; Keisuke Sakurada; Masaki Kobayashi; Shirou Itagaki; Takeshi Hirano; Ken Iseki
Journal:  Biol Pharm Bull       Date:  2008-03       Impact factor: 2.233

9.  Thalidomide metabolism by the CYP2C subfamily.

Authors:  Yuichi Ando; Eiichi Fuse; William D Figg
Journal:  Clin Cancer Res       Date:  2002-06       Impact factor: 12.531

Review 10.  Cytochrome p450 and chemical toxicology.

Authors:  F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2007-12-06       Impact factor: 3.739

View more
  13 in total

1.  In vivo formation of dihydroxylated and glutathione conjugate metabolites derived from thalidomide and 5-Hydroxythalidomide in humanized TK-NOG mice.

Authors:  Hiroshi Yamazaki; Hiroshi Suemizu; Makiko Shimizu; Sho Igaya; Norio Shibata; Masato Nakamura; Goutam Chowdhury; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2012-01-25       Impact factor: 3.739

2.  In vivo drug interactions of the teratogen thalidomide with midazolam: heterotropic cooperativity of human cytochrome P450 in humanized TK-NOG mice.

Authors:  Hiroshi Yamazaki; Hiroshi Suemizu; Norie Murayama; Masahiro Utoh; Norio Shibata; Masato Nakamura; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2013-03-01       Impact factor: 3.739

3.  Human cytochrome P450 oxidation of 5-hydroxythalidomide and pomalidomide, an amino analogue of thalidomide.

Authors:  Goutam Chowdhury; Norio Shibata; Hiroshi Yamazaki; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2013-12-24       Impact factor: 3.739

4.  The Dihydroxy Metabolite of the Teratogen Thalidomide Causes Oxidative DNA Damage.

Authors:  Tasaduq H Wani; Anindita Chakrabarty; Norio Shibata; Hiroshi Yamazaki; F Peter Guengerich; Goutam Chowdhury
Journal:  Chem Res Toxicol       Date:  2017-08-02       Impact factor: 3.739

Review 5.  Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction.

Authors:  Antonio Segovia-Zafra; Daniel E Di Zeo-Sánchez; Carlos López-Gómez; Zeus Pérez-Valdés; Eduardo García-Fuentes; Raúl J Andrade; M Isabel Lucena; Marina Villanueva-Paz
Journal:  Acta Pharm Sin B       Date:  2021-11-18       Impact factor: 11.413

6.  Thalidomide increases human hepatic cytochrome P450 3A enzymes by direct activation of the pregnane X receptor.

Authors:  Norie Murayama; Rinie van Beuningen; Hiroshi Suemizu; Christiane Guguen Guillouzo; Norio Shibata; Kanako Yajima; Masahiro Utoh; Makiko Shimizu; Christophe Chesné; Masato Nakamura; F Peter Guengerich; René Houtman; Hiroshi Yamazaki
Journal:  Chem Res Toxicol       Date:  2014-02-05       Impact factor: 3.739

7.  Assessment of Protein Binding of 5-Hydroxythalidomide Bioactivated in Humanized Mice with Human P450 3A-Chromosome or Hepatocytes by Two-Dimensional Electrophoresis/Accelerator Mass Spectrometry.

Authors:  Hiroshi Yamazaki; Hiroshi Suemizu; Yasuhiro Kazuki; Ken Oofusa; Shunji Kuribayashi; Makiko Shimizu; Shinichi Ninomiya; Toru Horie; Norio Shibata; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2016-07-29       Impact factor: 3.739

Review 8.  Combining Chimeric Mice with Humanized Liver, Mass Spectrometry, and Physiologically-Based Pharmacokinetic Modeling in Toxicology.

Authors:  Hiroshi Yamazaki; Hiroshi Suemizu; Marina Mitsui; Makiko Shimizu; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2016-07-05       Impact factor: 3.739

9.  Thalidomide-induced limb abnormalities in a humanized CYP3A mouse model.

Authors:  Yasuhiro Kazuki; Masaharu Akita; Kaoru Kobayashi; Mitsuhiko Osaki; Daisuke Satoh; Ryo Ohta; Satoshi Abe; Shoko Takehara; Kanako Kazuki; Hiroshi Yamazaki; Tetsuya Kamataki; Mitsuo Oshimura
Journal:  Sci Rep       Date:  2016-02-23       Impact factor: 4.379

10.  Effect of thalidomide on the proliferation of hepatoma cells assessed by osteopontin levels in nude mice.

Authors:  Fan Lin; Jie Cao; Zhiming Huang; Zhenghao Pei; Weili Gu; Shaofeng Fan; Kunping Li; Jiefeng Weng
Journal:  Exp Ther Med       Date:  2013-03-15       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.